The final rules of reverse CFIUS differ from the draft version; China changes its foreign investment rules to attract more long-term and high-quality investments; and Chinese data center company raises $1 billion from U.S. PE investors.
The world's largest drone manufacturer fights allegations by the U.S. Defense Department, Commerce Department, and House of Representatives; Chinese government invests in Chinese startups after U.S. venture capital and private equity funds leave China; and Chinese insurance regulator approves insurance firms set up by BNP Paribas and Prudential.
China allows fully foreign-owned hospitals and foreign investment in gene technologies; China is assessing the compatibility of the international AI agreement with its own strategic plans; and China's Ministry of Finance strengthens its regulation of foreign accounting organizations, particularly for those that do not have offices in China
U.S. lawmakers are worried about Microsoft's deal with a UAE-based AI company that has China ties; Nippon Steel ends joint venture with Baoshan; and China tightens regulation on hedge funds and programmed trading.
Germany's Economy Ministry blocks Volkswagen deal with Chinese company on national security grounds; China leads the world in the adoption of generative AI in banking and healthcare; and Chinese filmmakers wishing to submit short films to overseas film festivals must first register with authorities.
Alleged receiving of kickbacks by senior executives in China could subject Adidas to Chinese, as well as German and U.S. investigations; U.S. convertible bond market is used to raise funds by Chinese big tech amid IPO restrictions; and EU tariffs may lead to localization of Chinese EV production.
Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Shanghai FTZ expedites cross-border transfer of specified data; CBP investigation finds no substantial evidence of evasion by CIE; and Another Chinese EV SPAC merger is in the pipeline but EU tariffs threaten the business.
Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
